Comparative effectiveness of infliximab and tofacitinib in advanced therapy-naive and -exposed patients with ulcerative colitis: a multicenter real-world study
Inflammatory Bowel Diseases · 10.11.2026
DOI: 10.1093/ibd/izag248 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 10.11.2026. Verfasst von Noboru Mizuta und 13 weiteren Autor:innen. Beteiligte Einrichtung: 2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan. Die Arbeit nennt 23 Literaturangaben.
Abstract (Originalsprache)
Background and Aim: Infliximab (IFX) and tofacitinib (TOF) are advanced therapies for ulcerative colitis (UC), but real-world comparative data by prior advanced therapy (AT) exposure remain limited. We compared effectiveness by prior AT exposure.
Methods
This multicenter retrospective cohort study included adults with UC who initiated IFX or TOF between June 2010 and May 2025. The primary analysis was restricted to May 2018 onward, when both were available in Japan. AT-naive and AT-exposed cohorts were analyzed separately using overlap weighting. The primary outcome was corticosteroid-free clinical remission at week 52.
Results
Of 266 patients (137 IFX, 129 TOF), the primary analysis included 76 AT-naive (27 IFX, 49 TOF) and 120 AT-exposed (40 IFX, 80 TOF) patients. Week 14 remission did not differ significantly between treatments in either cohort. At week 52, remission numerically favored TOF in AT-naive patients (IFX, 43.9%; TOF, 64.5%; odds ratio [OR], 2.32; 95% CI, 0.84-6.44; P = .105), whereas remission was higher with TOF in the AT-exposed cohort (IFX, 19.0%; TOF, 38.8%; OR, 2.71; 95% CI, 1.08-6.80; nominal P = .034). Three-year treatment persistence did not differ significantly in either cohort but numerically favored TOF in AT-naive patients (IFX, 39.2%; TOF, 61.5%; hazard ratio, 0.64; 95% CI, 0.31-1.36). Multiple-imputation analyses yielded similar findings.
Conclusions
Week 52 remission numerically favored TOF in AT-naive patients and was higher with TOF in AT-exposed patients. Clinically relevant differences in 3-year persistence could not be ruled out, particularly in AT-naive patients. These findings are exploratory.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- 2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
- Department of Gastroenterology, Katsuragi Hospital, Osaka, Japan.
- Kinshukai Infusion Clinic, Osaka, Japan.
- Fujita Gastroenterological Hospital, Takatsuki, Japan.
- Department of Gastroenterology, Nara Prefecture General Medical Center, Nara, Japan.
ORCID-Profile: Noboru Mizuta, Naohiko Kinoshita, Kazuki Kakimoto, Hiroaki Ito, Hitoshi Hongo, Kei Moriya, Keijiro Numa, Kei Nakazawa, Ryoji Koshiba, Yuki Hirata, Takako Miyazaki, Shiro Nakamura, Hiroki Nishikawa
Zitieren
APA
Mizuta, N., Kinoshita, N., Kakimoto, K., Hara, A., Ito, H., Hongo, H., Moriya, K., Numa, K., Nakazawa, K., Koshiba, R., Hirata, Y., Miyazaki, T., Nakamura, S., & Nishikawa, H. (2026). Comparative effectiveness of infliximab and tofacitinib in advanced therapy-naive and -exposed patients with ulcerative colitis: a multicenter real-world study. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izag248
Vancouver
Mizuta N, Kinoshita N, Kakimoto K, Hara A, Ito H, Hongo H, et al. Comparative effectiveness of infliximab and tofacitinib in advanced therapy-naive and -exposed patients with ulcerative colitis: a multicenter real-world study. Inflammatory Bowel Diseases. 2026. doi:10.1093/ibd/izag248
BibTeX
@article{Mizuta2026,
author = {Mizuta, Noboru and Kinoshita, Naohiko and Kakimoto, Kazuki and Hara, Azusa and Ito, Hiroaki and Hongo, Hitoshi and Moriya, Kei and Numa, Keijiro and Nakazawa, Kei and Koshiba, Ryoji and Hirata, Yuki and Miyazaki, Takako and Nakamura, Shiro and Nishikawa, Hiroki},
title = {Comparative effectiveness of infliximab and tofacitinib in advanced therapy-naive and -exposed patients with ulcerative colitis: a multicenter real-world study},
journal = {Inflammatory Bowel Diseases},
year = {2026},
doi = {10.1093/ibd/izag248}
}
EUVIMED